Massive haemolysis in a group A recipient of a group O peripheral blood stem cell allogeneic transplant

被引:15
作者
Tiplady, CW [1 ]
Fitzgerald, JM [1 ]
Jackson, GH [1 ]
Conn, JS [1 ]
Proctor, SJ [1 ]
机构
[1] Royal Victoria Infirm, Dept Haematol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England
关键词
haemolysis; minor ABO incompatibility; peripheral blood stem cell transplant;
D O I
10.1046/j.1365-3148.2001.00334.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 28-year-old man with lymphoblastic lymphoma received G-CSF mobilized stem cells from his HLA identical sister, who had been taking methotrexate for psoriasis until 1 month prior to harvest. The recipient's blood group was A Rh D positive and donor's group O Rh D positive. Engraftment and major haemolysis were evident by day 9. From day 9 to day 13 he received 17 units of blood (approximately 3 L of red cells) at a time when his calculated red cell volume was 1 L. This massive transfusion requirement was not explained by his clinical condition and led us to consider factors that may have influenced the degree of haemolysis. The stem cell graft contained 2.85 x 10(6) CD34+ cells kg(-1) and we speculate there was B cell hyperactivity following the withdrawal of methotrexate in the donor and this went unchecked by the omission of methotrexate in the GVHD prophylaxis of the recipient. We have also considered the phenomenon of bystander haemolysis, previously unreported in this situation, as haemolysis of transfused group O blood must have also occurred. The case also illustrates the importance of transfusing donor type red cells and recipient type fresh frozen plasma (FFP) and platelets into minor mismatched transplant patients. The decision to revert to donor type FFP and platelets should only be made when the direct antiglobulin test is negative and the appropriate isohaemagglutinins are no longer demonstrable.
引用
收藏
页码:455 / 458
页数:4
相关论文
共 41 条
  • [31] A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response
    Robert M. Rifkin
    Andrew Greenspan
    John F. Schwerkoske
    Romeo A. Mandanas
    Joe J. Stephenson
    George T. Kannarkat
    Feng Zhan
    Kristi A. Boehm
    Lina Asmar
    Roy Beveridge
    Investigational New Drugs, 2012, 30 : 714 - 722
  • [32] A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response
    Rifkin, Robert M.
    Greenspan, Andrew
    Schwerkoske, John F.
    Mandanas, Romeo A.
    Stephenson, Joe J.
    Kannarkat, George T.
    Zhan, Feng
    Boehm, Kristi A.
    Asmar, Lina
    Beveridge, Roy
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 714 - 722
  • [33] High-dose chemotherapy plus peripheral blood stem cell transplantation for patients with relapsed germ cell tumors and active brain metastases
    Kalra, Maitri
    Adra, Nabil
    Hanna, Nasser
    Abonour, Rafat
    Einhorn, Lawrence H.
    CANCER, 2020, 126 (06) : 1202 - 1207
  • [34] Determination of ABO antibody titre and haemolysin test of group O whole blood used for exchanged transfusion in a teaching hospital
    Noor, Noor Haslina Mohd
    Hasan, Mohd Nazri
    Iberahim, Salfarina
    Zulkafli, Zefarina
    Yusuf, Shafini Mohd
    Bahar, Rosnah
    Ramli, Marini
    Rahman, Wan Suriana Wan Abdul
    Saidin, Nur Ilya Syazwani
    BANGLADESH JOURNAL OF MEDICAL SCIENCE, 2022, 21 (02): : 368 - 372
  • [35] Assessment of haematopoietic progenitor cell counting with the Sysmex® XN-1000 to guide timing of apheresis of peripheral blood stem cells
    Dima, Francesco
    Barison, Erika
    Midolo, Martina
    Benedetti, Fabio
    Lippi, Giuseppe
    BLOOD TRANSFUSION, 2020, 18 (01) : 67 - 76
  • [36] An uncommon case of late thrombotic thrombocytopenic purpura (42 months) after autologous peripheral blood stem cell (PBSC) transplantation in a child
    M González-Vicent
    M A Díaz
    L Madero
    Bone Marrow Transplantation, 1999, 23 : 735 - 736
  • [37] An uncommon case of late thrombotic thrombocytopenic purpura (42 months) after autologous peripheral blood stem cell (PBSC) transplantation in a child
    González-Vicent, M
    Díaz, MA
    Madero, L
    BONE MARROW TRANSPLANTATION, 1999, 23 (07) : 735 - 736
  • [38] A comparative study of peripheral blood stem cell vs bone marrow transplantation from unrelated donors (MUD): a single center study
    AA Fauser
    N Basara
    IW Blau
    MG Kiehl
    Bone Marrow Transplantation, 2000, 25 : S27 - S31
  • [39] A comparative study of peripheral blood stem cell vs bone marrow transplantation from unrelated donors (MUD):: a single center study
    Fauser, AA
    Basara, N
    Blau, IW
    Kiehl, MG
    BONE MARROW TRANSPLANTATION, 2000, 25 (Suppl 2) : S27 - S31
  • [40] A collaborative study by the Working Group on Hemostasis and Thrombosis of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC) on the interference of haemolysis on five routine blood coagulation tests by evaluation of 269 paired haemolysed/non-haemolysed samples
    Novelli, Chiara
    Vidali, Matteo
    Brando, Bruno
    Morelli, Benedetto
    Andreani, Giovanna
    Arini, Marina
    Calzoni, Paola
    Giacomello, Roberta
    Montaruli, Barbara
    Muccini, Emanuela
    Papa, Angela
    Pradella, Paola
    Ruocco, Lucia
    Siviero, Fosca
    Viola, Filomena Gemma
    Zanchetta, Mario
    Zardo, Lorena
    Lippi, Giuseppe
    BIOCHEMIA MEDICA, 2018, 28 (03)